Evotec AG announced that it has expanded the scope of its collaboration with MedImmune, LLC after hitting a key milestone. The company achieved a payment of EUR 0.5 million. This triggers a commercial license granted to MedImmune and an extension of the diabetes and beta cell regeneration collaboration to the end of 2013.

As part of the original agreement, the company received an upfront payment of EUR 5 million and could earn up to EUR 254 million in further and payments as well as royalties on product sales. The majority of payments are due upon achievement of certain clinical as well as regulatory and commercial milestones. Further the payments may be achieved with the approval of additional indications and programs.